Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Atherosclerosis ; 396: 118524, 2024 09.
Artigo em Inglês | MEDLINE | ID: mdl-38972156

RESUMO

BACKGROUND AND AIMS: In advanced atherosclerotic lesions, macrophage deaths result in necrotic core formation and plaque vulnerability. Cyclophilin D (CypD) is a mitochondria-specific cyclophilin involved in the process of cell death after organ ischemia-reperfusion. However, the role of CypD in atherosclerosis, especially in necrotic core formation, is unknown. Therefore, this experiment aims to clarify the role of CypD in necrotic core formation. METHODS: To clarify the specific role of CypD, encoded by Ppif in mice, apolipoprotein-E/CypD-double knockout (Apoe-/-Ppif-/-) mice were generated. These mice were fed a high-fat diet containing 0.15 % cholesterol for 24 weeks to accelerate atherosclerotic lesion development. RESULTS: Deletion of CypD decreased the necrotic core size, accompanied by a reduction of macrophage apoptosis compared to control Apoe-/- mice. In RAW264.7 cells, siRNA-mediated knockdown of CypD attenuated the release of cytochrome c from the mitochondria to the cytosol induced by endoplasmic reticulum stress inducer thapsigargin. In addition, necroptosis, induced by TNF-α and caspase inhibitor, was attenuated by knockdown of CypD. Ly-6Chigh inflammatory monocytes in peripheral blood leukocytes and mRNA expression of Il1b in the aorta were decreased by deletion of CypD. In contrast, siRNA-mediated knockdown of CypD did not significantly decrease Il1b nor Ccl2 mRNA expression in RAW264.7 cells treated with LPS and IFN-γ, suggesting that inhibition of inflammation in vivo is likely due to decreased cell death in the atherosclerotic lesions rather than a direct action of CypD deletion on the macrophage. CONCLUSIONS: These results indicate that CypD induces macrophage death and mediates necrotic core formation in advanced atherosclerotic lesions. CypD could be a novel therapeutic target for treating atherosclerotic vascular diseases.


Assuntos
Aterosclerose , Macrófagos , Mitocôndrias , Necrose , Peptidil-Prolil Isomerase F , Placa Aterosclerótica , Animais , Peptidil-Prolil Isomerase F/metabolismo , Peptidil-Prolil Isomerase F/genética , Macrófagos/metabolismo , Aterosclerose/patologia , Aterosclerose/metabolismo , Aterosclerose/genética , Camundongos , Mitocôndrias/metabolismo , Mitocôndrias/patologia , Células RAW 264.7 , Modelos Animais de Doenças , Apoptose , Camundongos Endogâmicos C57BL , Camundongos Knockout para ApoE , Necroptose , Masculino , Camundongos Knockout , Apolipoproteínas E/genética , Apolipoproteínas E/deficiência , Ciclofilinas/metabolismo , Ciclofilinas/genética , Ciclofilinas/deficiência , Dieta Hiperlipídica , Interleucina-1beta/metabolismo , Antígenos Ly
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA